Delivery Order SPE2DB20D1110-SPE2DB25FK28F
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,083.49 to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 80-12.5 mg tablets in unit dose packaging (30 count) under a firm fixed price contract. This delivery order, which was competitively awarded with no set-aside designation, was executed on July 23, 2025, with an ultimate completion date of July 24, 2025. Performance will take place at the contractor's Corporate Office location in Conshohocken, Pennsylvania....
- The Defense Logistics Agency awarded a $14,672.56 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packaging (30-count). The contract is structured as a firm fixed price delivery order with a completion date of July 25, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was applied to this competitively awarded contract. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,675.75 to AmerisourceBergen Drug Corp for the supply of Telmisartan-HCTZ 80-25 mg tablets in unit dose packaging (30-count), with a firm fixed price and an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract was issued on July 25, 2025, with performance at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The award, valued at $56,821.15, is a Firm Fixed Price Delivery Order contract for the supply of Telmisartan-HCTZ 40-12.5 mg tablets. The contract has an ultimate completion date of November 5, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth $16,557.69 to AmerisourceBergen Drug Corp, a subsidiary of AmerisourceBergen Corporation, to provide Telmisartan-HCTZ 80-25 mg tablets in 30-count packages. The contract has a performance period through March 18, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) awarded by DLA to AmerisourceBergen Drug Corp with a potential value of $999,999,999.00 and a performance...
- This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $2,197.29, is for the delivery of Telmisartan-HCTZ 40-12.5 mg tablets in 30-count units. The contract has an ultimate completion date of April 14, 2025 and is a firm fixed-price delivery order. No set-aside was used for this award. AmerisourceBergen holds a significant Indefinite Delivery Contract...
- This is a federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The $1,394.90 delivery order contract is for the supply of Telmisartan-HCTZ 80-25 mg tablets. It is a firm fixed-price, non-set-aside contract with a completion date of June 16, 2025. AmerisourceBergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive global...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Telmisartan-HCTZ 40-12.5 mg tablets. The $2,643.33 firm fixed price contract has a completion date of February 24, 2025. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,111.53 firm fixed-price order is for Telmisartan-HCTZ 40-12.5 mg tablets, a cardiovascular medication. The award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC...
- This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award, valued at $4,255.27, is for the delivery of Telmisartan-HCTZ 80-25 mg tablets. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of July 29, 2024. AmerisourceBergen has an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running...
- SPE2DB20D1110Indefinite Delivery Contract
- SPE2DB20D1110-SPE2DB25FK28FDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,007.04 to AmerisourceBergen Drug Corp for Telmisartan-HCTZ 40-12.5 mg tablets in unit dose packages of 30 units. This competitive award, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, utilizes firm fixed pricing and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. No set-aside designation was applied to this award. This delivery order falls under AmerisourceBergen's comprehensive $999,999,999.00 Indefinite Delivery/Indefinite Quantity contract with DLA Troop Support Medical (designated SPE2DX), which extends through December 2026 and serves as a global pharmaceutical support vehicle for military healthcare systems. As a major pharmaceutical distributor and critical federal vendor, AmerisourceBergen maintains an extensive portfolio of generic and brand-name medications, vaccines, and medical supplies across multiple therapeutic domains. The company's federal contracts support the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, with DLA planning to establish next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts involving multiple regional contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.0k | 7/22/25 |